FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Shanahan

Research Profile

Chemicals & Drugs

Procedures

Disorders

Devices

Placebos

Concepts & Ideas

Treatment Outcome

Activities & Behaviors

Living Beings

Genetically Modified Animals

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Barry D Kahan; Stanislaw M Stepkowski; Murat Kilic; Stephen M Katz; Charles T Van Buren; Maria S Welsh; Joseph A Tami; William R Shanahan
Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Bruce R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; Joseph A Tami; R Yu; E Gibiansky; William R Shanahan
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Walter P Maksymowych; Warren D Blackburn; Joseph A Tami; William R Shanahan
A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Shanahan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Barry D Kahan; Stanislaw M Stepkowski; Murat Kilic; Stephen M Katz; Charles T Van Buren; Maria S Welsh; Joseph A Tami; William R Shanahan
Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Transplantation 2004;78(6):858-63.
2002: Bruce R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; Joseph A Tami; R Yu; E Gibiansky; William R Shanahan
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Gut 2002;51(1):30-6.
2002: Walter P Maksymowych; Warren D Blackburn; Joseph A Tami; William R Shanahan
A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
The Journal of rheumatology 2002;29(3):447-53.
1999: Bruce R Yacyshyn; William R Shanahan
Making sense of antisense.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 1999;13(9):745-51.
1999: Eric G Marcusson; Bruce R Yacyshyn; William R Shanahan; Nicholas Dean
Preclinical and clinical pharmacology of antisense oligonucleotides.
Molecular biotechnology 1999;12(1):1-11.
1999: Bruce R Yacyshyn; Mary Beth Bowen-Yacyshyn; William R Shanahan
The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
Current opinion in molecular therapeutics 1999;1(3):332-5.
1998: Bruce R Yacyshyn; Mary Beth Bowen-Yacyshyn; Laurence D Jewell; Joseph A Tami; C F Bennett; D L Kisner; William R Shanahan
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
Gastroenterology 1998;114(6):1133-42.
1997: J M Glover; JM Leeds; Timothy G K Mant; Dipti M Amin; D L Kisner; J E Zuckerman; Richard S Geary; Arthur A Levin; William R Shanahan
Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
The Journal of pharmacology and experimental therapeutics 1997;282(3):1173-80.